ZIOPHARM Oncology, Inc. (ZIOP) Income Statement Analysis

See more : GOLDCREST Co.,Ltd. (CDCTF) Income Statement Analysis – Financial Results

Complete financial analysis of ZIOPHARM Oncology, Inc. (ZIOP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZIOPHARM Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Ermenegildo Zegna N.V. (ZGN) Income Statement Analysis – Financial Results
Aurora Cannabis Inc. (21P1.F) Income Statement Analysis – Financial Results
Pettenati S.A. Industria Têxtil (PTNT4.SA) Income Statement Analysis – Financial Results
Biomagnetics Diagnostics Corp. (BMGP) Income Statement Analysis – Financial Results
Zaklady Azotowe Pulawy S.A. (ZAP.WA) Income Statement Analysis – Financial Results

ZIOPHARM Oncology, Inc. (ZIOP)

Industry: Biotechnology

Sector: Healthcare

Website: https://ziopharm.com

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Metric	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Revenue	0.00	0.00	146.00K	6.39M	6.86M	4.33M	1.37M	800.00K	800.00K	667.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.57K	1.73K
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	146.00K	6.39M	6.86M	4.33M	1.37M	800.00K	800.00K	667.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.57K	1.73K
Gross Profit Ratio	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%
Research & Development	52.70M	38.33M	34.13M	45.08M	157.79M	106.79M	32.71M	42.85M	83.45M	57.08M	12.91M	4.56M	17.25M	18.99M	10.39M	5.59M	0.00	0.00	0.00	0.00
General & Administrative	27.67M	19.53M	19.92M	14.80M	14.38M	17.65M	12.17M	15.66M	19.52M	14.98M	11.64M	7.57M	8.37M	9.58M	8.72M	4.19M	39.17K	35.36K	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	120.00
SG&A	27.67M	19.53M	19.92M	14.80M	14.38M	17.65M	12.17M	15.66M	19.52M	14.98M	11.64M	7.57M	8.37M	9.58M	8.72M	4.19M	39.17K	35.36K	0.00	120.00
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	486.00	-42.51K	74.14K
Operating Expenses	80.36M	57.86M	54.05M	59.88M	172.17M	124.43M	44.87M	58.51M	102.97M	72.07M	24.55M	12.12M	25.62M	28.57M	19.11M	9.79M	39.17K	35.84K	-42.51K	74.26K
Cost & Expenses	80.36M	57.86M	54.05M	59.88M	172.17M	124.43M	44.87M	58.51M	102.97M	72.07M	24.55M	12.12M	25.62M	28.57M	19.11M	9.79M	39.17K	35.84K	42.51K	74.26K
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	388.00K	1.96M	1.25M	270.48K	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.13M	629.00K	575.00K	369.00K	290.00K	357.00K	462.00K	738.00K	658.00K	268.00K	188.00K	330.00K	388.00K	433.35K	173.92K	101.23K	0.00	486.00	799.00	750.00
EBITDA	-78.85M	-117.17M	-52.54M	-53.95M	-165.01M	-119.73M	-31.32M	-56.37M	-95.47M	-63.51M	-32.48M	-7.32M	-24.84M	-26.17M	-17.68M	-9.42M	-39.17K	-35.36K	-39.14K	-71.79K
EBITDA Ratio	0.00%	0.00%	-35,987.67%	-844.48%	-2,405.00%	-2,763.87%	-2,281.06%	-7,046.13%	-11,934.25%	-9,521.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,523.04%	-4,159.04%
Operating Income	-79.98M	-117.80M	-53.12M	-54.32M	-165.30M	-120.09M	-31.78M	-57.11M	-96.13M	-63.78M	-32.67M	-7.65M	-25.23M	-26.61M	-17.86M	-9.52M	-39.17K	-35.84K	-39.94K	-72.54K
Operating Income Ratio	0.00%	0.00%	-36,381.51%	-850.26%	-2,409.23%	-2,772.11%	-2,314.71%	-7,138.38%	-12,016.50%	-9,561.92%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,554.12%	-4,202.49%
Total Other Income/Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.62M	-8.12M	4.47M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Before Tax	-79.98M	-117.80M	-53.12M	-54.32M	-165.30M	-120.09M	-31.78M	-57.11M	-96.13M	-56.16M	-40.79M	-3.18M	0.00	0.00	0.00	0.00	-39.17K	-35.84K	-39.94K	-72.54K
Income Before Tax Ratio	0.00%	0.00%	-36,381.51%	-850.26%	-2,409.23%	-2,772.11%	-2,314.71%	-7,138.38%	-12,016.50%	-8,419.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,554.12%	-4,202.49%
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.62M	-8.12M	4.47M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-79.98M	-117.80M	-53.12M	-54.32M	-165.30M	-120.09M	-31.78M	-57.11M	-96.13M	-63.78M	-32.67M	-7.65M	-25.23M	-26.61M	-17.86M	-9.52M	-39.17K	-35.84K	-39.94K	-72.54K
Net Income Ratio	0.00%	0.00%	-36,381.51%	-850.26%	-2,409.23%	-2,772.11%	-2,314.71%	-7,138.38%	-12,016.50%	-9,561.92%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,554.12%	-4,202.49%
EPS	-0.38	-0.70	-0.37	-0.40	-1.27	-0.96	-0.31	-0.66	-1.22	-0.97	-0.71	-0.33	-1.19	-1.41	-1.42	-2.32	-0.29	-0.31	-0.36	-0.80
EPS Diluted	-0.38	-0.70	-0.37	-0.40	-1.27	-0.96	-0.31	-0.66	-1.22	-0.97	-0.71	-0.33	-1.19	-1.41	-1.42	-2.32	-0.29	-0.31	-0.36	-0.80
Weighted Avg Shares Out	209.64M	167.95M	143.71M	136.94M	130.39M	125.42M	101.13M	85.94M	78.55M	66.00M	46.00M	23.11M	21.23M	18.83M	12.57M	4.10M	135.99K	116.82K	112.49K	90.27K
Weighted Avg Shares Out (Dil)	209.64M	167.95M	143.71M	136.94M	130.39M	125.42M	101.13M	85.94M	78.55M	66.00M	46.00M	23.11M	21.23M	18.83M	12.57M	4.10M	135.99K	116.82K	112.49K	90.27K

Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

January 19, 2022fool.com

The clinical-stage biotech saw a slight bounce-back from its lows of last week.

ZIOPHARM Oncology (ZIOP) Sees Hammer Chart Pattern: Time to Buy?

November 23, 2021zacks.com

ZIOPHARM Oncology (ZIOP) has been struggling lately, but the selling pressure may be coming to an end soon.

ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript

November 8, 2021seekingalpha.com

ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript

Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

November 1, 2021globenewswire.com

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close...